DM 199

Drug Profile

DM 199

Alternative Names: DM-199; DM-99; Recombinant human tissue kallikrein-1 - DiaMedica Therapeutics; rhKLK-1 - DiaMedica

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DiaMedica
  • Developer DiaMedica; DiaMedica Therapeutics
  • Class Antidementias; Antihyperglycaemics; Antirheumatics; Insulin sensitisers; Nootropics; Recombinant proteins
  • Mechanism of Action Insulin receptor agonists; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Stroke; Type 2 diabetes mellitus
  • Preclinical Nephritis
  • Research Acute kidney injury
  • No development reported Alzheimer's disease; Diabetic nephropathies; Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 22 Nov 2017 The Australian Human Research Ethics Committee approves the first clinical site to initiate the phase II REMEDY trial in Australia
  • 07 Nov 2017 Pharmacokinetics data from a phase Ib trial in Stroke (In volunteers) released by DiaMedica Therapeutics
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Diabetic-nephropathies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top